Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in
J
apanese patients with type 2 diabetes: a 26‐week randomized phase
III
study
2015 ◽
Vol 17
(10)
◽
pp. 974-983
◽
Keyword(s):
2016 ◽
Vol 18
(3)
◽
pp. 249-257
◽
Keyword(s):
2017 ◽
Vol 37
(8)
◽
pp. 927-943
◽
Keyword(s):
2013 ◽
Vol 02
(01)
◽
2010 ◽
Vol 2
◽
pp. CMT.S4148
◽
2016 ◽
Vol 18
(7)
◽
pp. 725-728
◽
Keyword(s):